



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : C12N 15/86, 15/62, C07K 14/16, C12N 7/01, A61K 48/00		A2	(11) International Publication Number: WO 99/61639
(21) International Application Number: PCT/GB99/01607		(43) International Publication Date: 2 December 1999 (02.12.99)	
(22) International Filing Date: 21 May 1999 (21.05.99)			
(30) Priority Data: 9811153.7 22 May 1998 (22.05.98) GB 60/093,149 17 July 1998 (17.07.98) US			
(71) Applicant (for all designated States except US): OXFORD BIOMEDICA (UK) LIMITED [GB/GB]; Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB).			
(72) Inventors; and (75) Inventors/Applicants (for US only): MITRAPHANOUS, Kyr- iacos, Andreou [GR/GB]; Oxford BioMedica (UK) Limited, Medawar Centre, Robert Robinson Avenue, The Oxford Sci- ence Park, Oxford OX4 4GA (GB); PATIL, Deva [IN/GB]; University of Oxford, Dept. of Biochemistry, South Parks Road, Oxford OX1 3QU (GB); KINGSMAN, Alan, John [GB/GB]; Oxford BioMedica (UK) Limited, Medawar Cen- tre, Robert Robinson Avenue, The Oxford Science Park, Ox- ford OX4 4GA (GB); KINGSMAN, Susan, Mary [GB/GB]; Oxford BioMedica (UK) Limited, Medawar Centre, Robert Robinson Avenue, The Oxford Science Park, Oxford OX4 4GA (GB); ELLARD, Fiona, Margaret [GB/GB]; Oxford			
		(74) Agents: HARDING, Charles, Thomas et al.; D. Young & Co., 21 New Fetter Lane, London EC4A 1DA (GB).	
		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).	
		Published <i>Without international search report and to be republished upon receipt of that report.</i>	



(54) Title: RETROVIRAL DELIVERY SYSTEM

(57) Abstract



A retroviral delivery system capable of transducing a target site is described. The retroviral delivery system comprises a first nucleotide sequence coding for at least a part of an envelope protein; and one or more other nucleotide sequences derivable from a retrovirus that ensure transduction of the target site by the retroviral delivery system; wherein the first nucleotide sequence is heterologous with respect to at least one of the other nucleotide sequences; and wherein the first nucleotide sequence codes for at least a part of a rabies G protein or a mutant, variant, derivative or fragment thereof that is capable of recognising the target site.

Description of vectors used in pseudotyping experiments.

HIV-1 vectors.



EIAV vectors.



MLV vectors.

